The company"s consolidated revenue for Q1"2011 grew by 31 per cent to Rs 4,981 million as against Rs 3,815 million for the year ago period of 2010.
For the same period, the company"s consolidated EBIDTA recorded a 19 per cent growth while its speciality business grew by 93 per cent over the year ago period of 2010. Also, the consolidated PAT (before minority) stood at Rs. 451 million, registering a year-on- year growth of 5 per cent over Q1" 2010.
The company develops and manufactures IP led niche pharmaceutical products with a stress on sterile injectables.
In addition, the company was recently given a USFDA sanction for its new sterile injectable facility at Bangalore and had commenced the sales to US markets from the same unit. The company also reported that it had received the first oncology approval from Europe.
Currently on the Bombay Stock Exchange (BSE), stocks of the firm are trading at Rs. 393.55 down by 3.20 points or by 0.81 per cent. So far, the stock has seen an intraday high of Rs. 412.60 and an intraday low of Rs. 390.90. (2:50 P.M IST)